HALOPERIDOL LA 50 MG
HALOPERIDOL (HALOPERIDOL DECANOATE) : 50 MG · DIN 02130297 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED POST MARKET
What is HALOPERIDOL LA?
HALOPERIDOL LA 50 MG contains HALOPERIDOL (HALOPERIDOL DECANOATE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02130297, held by SANDOZ CANADA INCORPORATED, supplied as LIQUID for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HALOPERIDOL LA used for?
Management of manifestations of chronic schizophrenia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02130297 |
|---|---|
| Brand name | HALOPERIDOL LA |
| Generic / active ingredient | HALOPERIDOL (HALOPERIDOL DECANOATE) : 50 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 50 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | N05AD01 HALOPERIDOL |
| AHFS class | 28:16.08.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jul-2025 |
| Original market date | 1994-12-31 00:00:00 |
How is it administered?
For IM injection only. Initial dose often 20 times the daily oral dose. Usually administered every 4 weeks. Individualize dosage based on patient response.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text.
How is it supplied?
Not explicitly detailed in the provided text (mentions 50 mg/mL and 100 mg/mL concentrations).
Contraindications
Intravenous use; comatose states; CNS depression (alcohol/drugs); severe depressive states; spastic diseases; basal ganglia lesions; Parkinson’s syndrome; children; sensitivity to the drug.
Warnings and precautions
Sudden death, QT prolongation, and Torsade de Pointes reported. Risk of Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia, and Venous Thromboembolism. May impair driving ability.
Is HALOPERIDOL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05AD01 HALOPERIDOL. 9 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HALOPERIDOL INJ 5MG/ML USP | 5 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00808652 |
| HALOPERIDOL INJECTION | 5 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02366010 |
| HALOPERIDOL INJECTION, USP | 5 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02406411 |
| HALOPERIDOL LA | 100 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02130300 |
| TEVA-HALOPERIDOL | 0.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00363685 |
| TEVA-HALOPERIDOL | 1 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00363677 |
| TEVA-HALOPERIDOL | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00713449 |
| TEVA-HALOPERIDOL | 2 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00363669 |
| TEVA-HALOPERIDOL | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00363650 |
| APO HALOPERIDOL TAB 0.5MG | .5 MG | TABLET | APOTEX INC | DORMANT | DIN 00396796 |
Who else supplies HALOPERIDOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HALOPERIDOL appears in 2739 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.